sb 203580 has been researched along with semapimod in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (semapimod) | Trials (semapimod) | Recent Studies (post-2010) (semapimod) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 83 | 4 | 19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foxwell, BM; Hunt, AE; Lali, FV; Lord, JD; Miyazaki, T; Nelson, BH; Tracey, KJ | 1 |
| dela Cruz, VF; Dewil, M; Robberecht, W; Van Den Bosch, L | 1 |
2 other study(ies) available for sb 203580 and semapimod
| Article | Year |
|---|---|
Role of interleukin (IL)-2 receptor beta-chain subdomains and Shc in p38 mitogen-activated protein (MAP) kinase and p54 MAP kinase (stress-activated protein Kinase/c-Jun N-terminal kinase) activation. IL-2-driven proliferation is independent of p38 and p5
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Line; Enzyme Activation; Enzyme Inhibitors; Hydrazones; Imidazoles; Interleukin-2; Mice; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyridines; Receptors, Interleukin-2; T-Lymphocytes | 1999 |
Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1(G93A)-induced motor neuron death.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Axons; Cell Death; Cell Survival; Enzyme Activation; Enzyme Inhibitors; Hydrazones; Imidazoles; Mice; Mice, Transgenic; Motor Neurons; Mutation; Nerve Degeneration; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Pyridines; Superoxide Dismutase | 2007 |